ClinicaliQ Trial Snapshot
- Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients — Recruiting • Phase II • NCT07287189.
- SAT-3247 tested at two doses versus placebo in children aged 7-10 with muscular dystrophy over 12 weeks to find the best dose and safety profile.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and < 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy. Conditions: Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies Interventions: SAT-3247, Placebo Lead Sponsor: Satellos Bioscience, Inc. Planned Enrollment: 51 participants